헬리코박터 파일로리균 감염에 대한 IMMULITE2000®의 GENEDIA®와의 정확성 비교
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 임선희 | - |
dc.contributor.author | 김나영 | - |
dc.contributor.author | 김성은 | - |
dc.contributor.author | 백광호 | - |
dc.contributor.author | 이주엽 | - |
dc.contributor.author | 박경식 | - |
dc.contributor.author | 신정은 | - |
dc.contributor.author | 송현주 | - |
dc.contributor.author | 명대성 | - |
dc.contributor.author | 최석채 | - |
dc.contributor.author | 김현진 | - |
dc.date.accessioned | 2022-12-26T13:47:24Z | - |
dc.date.available | 2022-12-26T13:47:24Z | - |
dc.date.created | 2022-12-14 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1738-3331 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gnu/handle/sw.gnu/7913 | - |
dc.description.abstract | Background/Aims: In serological tests for Helicobacter pylori (H. pylori), an enzyme-linked immunosorbent assay (GENEDIA®) and a solid-phase, two-step chemiluminescent enzyme immunoassay (IMMULITE®), which are easy to perform, inexpensive, and widely available, are commonly used. However, local validation of the test performance of IMMULITE® is required. This study aimed to examine the performance of IMMULITE® in comparison with that of GENEDIA® in a Korean health checkup population. Materials and Methods: The sera of 300 subjects among those who underwent health checkup were analyzed using IMMULITE®, and results were compared with those of GENEDIA®. The two serological tests were compared for their ability to predict atrophic gastritis (AG) or intestinal metaplasia (IM) on endoscopy. Results: We found significant correlation (Pearson correlation coefficient=0.903, P<0.0001) and an almost perfect agreement (Cohen’s Kappa coefficient=0.987, P<0.0001) between the results of GENEDIA® and IMMULITE®. The area under the receiver operating characteristics curve (AUC) for AG using GENEDIA® and IMMULITE® were 0.590 and 0.604, respectively, and showed no statistically significant difference in predictive ability for AG (Z-statistics=-0.517, P=0.605). The AUC for IM by GENEDIA® and IMMULITE® were 0.578 and 0.593, respectively, with no statistically significant difference in predictive ability for IM between the two values (Z-statistics=-0.398, P=0.691). Conclusions: No statistically significant difference in diagnostic value for H. pylori infection was found between GENEDIA® and IMMULITE®. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한상부위장관ㆍ헬리코박터학회 | - |
dc.title | 헬리코박터 파일로리균 감염에 대한 IMMULITE2000®의 GENEDIA®와의 정확성 비교 | - |
dc.title.alternative | A Comparison of Accuracy between IMMULITE2000® and GENEDIA® for Helicobacter pylori Infection | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 김현진 | - |
dc.identifier.doi | 10.7704/kjhugr.2019.0014 | - |
dc.identifier.bibliographicCitation | Korean Journal of Helicobacter Upper Gastrointestinal Research, v.20, no.1, pp.54 - 62 | - |
dc.relation.isPartOf | Korean Journal of Helicobacter Upper Gastrointestinal Research | - |
dc.citation.title | Korean Journal of Helicobacter Upper Gastrointestinal Research | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 54 | - |
dc.citation.endPage | 62 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002563680 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Enzyme-linked immunosorbent assay | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Immunoenzyme techniques | - |
dc.subject.keywordAuthor | Serology | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0533
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.